Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Yung Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.
Cited by 3,836 works. doi:10.1200/jco.2009.26.3541
Authors
- Patrick Yung Wen
- David R. Macdonald
- David A. Reardon
- Timothy Francis Cloughesy
- Alma Gregory Sorensen
- Evanthia Galanis
- John F DeGroot
- Wolfgang Wick
- Mark R. Gilbert
- Andrew B. Lassman
- Christina I. Tsien
- Tom Mikkelsen
- Eric T. Wong
- Marc Charles Chamberlain
- Roger Stupp
- Kathleen R. Lamborn
- Michael A. Vogelbaum
- Martin J. van den Bent
- Susan Marina Chang
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Reporting results of cancer treatment
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- WHO handbook for reporting results of cancer treatment
- Response criteria for phase II studies of supratentorial malignant glioma.
- Malignant Gliomas in Adults
- Modes of resistance to anti-angiogenic therapy
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis